We are live on ! Find out more

TCGX

TCGX Acquisition Corp

TCGX

Market cap $113M

10.02 USD

-0.03

0.3%

At close Updated Nov 10, 3:11 PM EST

1 day

-0.3%

5 days

-0.3%

1 month

-18.67%

3 months

-29.24%

6 months

-6.79%

Year to date

-6.79%

1 year

-6.79%

5 years

-6.79%

10 years

-6.79%

About: TCGX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

Financials Shell Companies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced that Daniel Lynch has been appointed Chairman of the TriGemX Bio Board of Directors (the “Board”). Mr. Lynch will remain Chairman of the Board following the closing of the previously an.

TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors

TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX) (“TCGX”), a publicly listed special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) to the U.S. Securities and Exchange Commission (“SEC”). The submission of the Re.

TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”.

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

See News Rankings

Price charts implemented using Lightweight Charts™